Albert Einstein College of Medicine receives $8 million from NIH to study how cancer spreads

November 03, 2011

Bronx, NY -- The National Cancer Institute (NCI) has awarded Albert Einstein College of Medicine of Yeshiva University two grants totaling $8 million to study the microenvironments that drive the spread of cancer from the primary tumor to other parts of the body in the process known as metastasis.

"Although metastasis is responsible for the vast majority of cancer-related deaths, our understanding of this complex process is extremely limited and so are the opportunities for preventing metastatic disease," said John Condeelis, Ph.D., professor and co-chair of anatomy and structural biology, co-director of the Gruss Lipper Biophotonics Center, director of the program in microenvironment and metastasis in the Albert Einstein Cancer Center, and holder of the Judith and Burton P. Resnick Chair in Translational Research at Einstein. Dr. Condeelis is a principal investigator on both grants.

The first grant, for $4 million over five years, will establish a tumor microenvironment research center (TMEN Center) at Einstein, one of 11 new national centers created by NCI's Tumor Microenvironment Network. The Einstein center will be led by principal investigator Dr. Condeelis and co-principal investigator Vladislav Verkhusha, Ph.D., professor of anatomy and structural biology.

The scientists will study two types of primary-tumor microenvironments. The first type programs cancer cells to disseminate from the primary tumor as dormant tumor cells. These cells eventually awaken after many years and give rise to recurrent cancers at distant sites--a condition currently not possible to detect and treat. Also under investigation is the type of microenvironment that controls whether disseminating tumor cells will grow immediately upon arrival at distant sites and are therefore sensitive to treatment.

The research will focus on breast and head and neck tumors, but the results should be applicable to a wide variety of solid tumors. Other investigators on this grant are from Mount Sinai School of Medicine, New York; College of Nanoscale Science & Engineering, University at Albany, State University of New York; and the University of Wisconsin-Madison.

In a second $4 million NCI grant, titled "In vivo multiphoton based imaging of complex cancer cell behavior," Einstein investigators will study the spread of breast tumor cells from the primary tumor using cutting-edge research methods including: high-resolution multiphoton microscopy (capable of imaging breast tumors at the single-cell level), advanced fluorescent proteins (which allow multicolor deep-tissue imaging and studies of dynamics of metastasis), and a novel methodology that uses computer modeling to analyze cancer (which may be able to identify the genes that propel cell migration, dissemination and other tumor-cell behaviors involved in metastasis).

One important factor in securing the grants is the advanced imaging capacity of the Gruss Lipper Biophotonics Center, which was established through the generous support of Evelyn Gruss Lipper, M.D., an Einstein alumna, former faculty member and former member of the Board of Overseers. "Due to her generosity, this combination of technologies is unique to Einstein," said Dr. Condeelis.
-end-
The three principal investigators on the second grant are Dr. Verkhusha, Dr. Condeelis, and Aviv Bergman, Ph.D., professor and founding chair of systems & computational biology.

About Albert Einstein College of Medicine of Yeshiva University

Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. During the 2010-2011 academic year, Einstein is home to 724 M.D. students, 256 Ph.D. students,122 students in the combined M.D./Ph.D. program, and 375 postdoctoral research fellows. The College of Medicine has 2,770 full time faculty members located on the main campus and at its clinical affiliates. In 2010, Einstein received nearly $200 million in support from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five medical centers in the Bronx, Manhattan and Long Island - which includes Montefiore Medical Center, The University Hospital and Academic Medical Center for Einstein - the College of Medicine runs one of the largest post-graduate medical training programs in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training. For more information, please visit http://www.einstein.yu.edu.

Albert Einstein College of Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.